Big Pharma Gets Flexible As Licensing Activity Heats Up
Executive Summary
Many pharmaceutical manufacturers are adopting new approaches to licensing deals as competition to fill pipelines intensifies and firms scramble to gain rights to innovative compounds and technologies
You may also be interested in...
Licensing An Adjunct To In-House R&D, Not A Substitute – AstraZeneca Exec
AstraZeneca views licensing and acquisitions as an add-on to, rather than a replacement for, internal research & development, Exec Director-Development John Patterson said Sept. 19
Licensing An Adjunct To In-House R&D, Not A Substitute – AstraZeneca Exec
AstraZeneca views licensing and acquisitions as an add-on to, rather than a replacement for, internal research & development, Exec Director-Development John Patterson said Sept. 19
Garnier’s Vision: GSK To Be “The Most R&D Intensive Company In The World”
GlaxoSmithKline appears ready to turn the typical pharmaceutical company business model on its head, with plans to significantly increase the percentage of sales spent on research & development and reduce spending on selling, general & administrative expenses